The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Biosimilars, pricing and related
Biosimilar medicines
Position paper
A position paper on biosimilar medicines will be presented to the GA in June. The paper focuses on naming of biosimilar medicines, extrapolation of indications, interchangeability, switching and substitution of biosimilar medicines, information about biosimilar medicines and the role of the hospital pharmacists.
EAHP’s views on these points are displayed in a short summary table at the beginning. The draft policy statement is shorter than the one presented at last year’s GA and solely focuses on the important points.
The Board Meeting provides an opportunity to discuss the POSITION PAPER
Updated version
Lecture by EMA speaker at GA
Since the level of knowledge of the members attending the GA ranges from no knowledge to very good knowledge on biosimilars it was decided to hold a session titled “Biosimilars – what should hospital pharmacists know?” at the GA. EMA has been approached to provide us with a speaker from the Biosimilar Medicinal Products Working Party.
The speaker will be giving a short introduction to biosimilar medicines taking into account EAHP’s views on biosimilar medicines presented in the policy paper.
Commission stakeholder event on biosimilar medicinal products
The European Commission (DG Growth) will be holding an event on biosimilars on 5th May 2017. Hospital pharmacists Thijs Giezens is part of the panel on “Collaborative Approach in the Use of Biosimilar Medicines”. The meeting will also be attended by Frank Jørgensen, François Bocquet and Stephanie Kohl will be attending the meeting.
EAHP also actively took part in shaping the draft agenda.